company

ACADIA Pharmaceuticals Inc.

ACADAcadia Pharms Inc
CIK 0001070494ticker ACAD
as of 2026-07-01
Monitor thisAsk about this
at a glance
Cash $282.2M (as of 2026-03-31)
Revenue $268.1M
11 trials sponsored · 2 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
Cash$282.2M2026-03-31
Ga Expense$171.0M2026-03-31
Net Income Loss$3.6M2026-03-31
Revenue$268.1M2026-03-31
Rnd Expense$76.9M2026-03-31
Stockholders Equity$1.2B2026-03-31
Total Assets$1.6B2026-03-31

Pipeline

2 assets
PimavanserinACP-104

Recent filings

SEC EDGAR
4open ↗2026-06-29
144open ↗2026-06-26
S-8open ↗2026-06-10
4open ↗2026-06-02
4open ↗2026-06-01
4open ↗2026-06-01
4open ↗2026-06-01
4open ↗2026-06-01
4open ↗2026-06-01
4open ↗2026-06-01
8-Kopen ↗2026-05-29
4open ↗2026-05-27

Facts & assertions

8 sourced
Financial Status
profitable
Latest Cash
282,212,000
Latest Ga Expense
171,019,000
Latest Net Income Loss
3,637,000
Latest Revenue
268,062,000
Latest Rnd Expense
76,868,000
Latest Stockholders Equity
1,248,066,000
Latest Total Assets
1,605,230,000
relationships
The graph out of here
asset
Pimavanserin
small molecule
drug
ACP-104
small molecule
drug